CrossRef 23. Steinberg HO, Proteasome inhibitor Brechtel G, Johnson A, Fineberg N, Baron AD: Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. Clin Invest 1994,94(3):1172–1179.CrossRef 24. Arenas J, Huertas R, Campos Y, Diaz E, et al.: Respiratory chain enzymes in muscle of endurance athletes: effect of L-carnitine. Biochem Biophys Res Commun 1992, 188:102–107.CrossRefPubMed

25. Arenas J, Ricox JR, Encinas AR, Pola P, et al.: HDAC inhibitor Effects of L-carnitine on the pyruvate dehydrogenase complex and carnitine palmitoyl transferase activities in muscle of endurance athletes. FEBS Lett 1994, 341:91–93.CrossRefPubMed 26. Huertas R, Campos Y, Diaz E, et al.: Respiratory chain GDC0449 enzymes in muscle of endurance athletes: effect of L-carnitine. Biochem Biophys Res Commun 1992, 188:102–107.CrossRefPubMed

27. Anand I, Chandrashekhan Y, De Guili F, Pasini E, et al.: Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998, 12:291–299.CrossRefPubMed 28. Dal Lago A, De Martini D, Flore R, et al.: Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs Exp Clin Res 1999, 25:29–36.PubMed 29. Podoprigora GI, Nartsissov YR, Aleksandrov PN: Effect of glycine on microcirculation in pial vessels of rat brain. Bull Exp Biol Med 2005, 139:675–677.CrossRefPubMed 30. Smith WA, Fry AC, Tschume LC, Bloomer RJ: Effect of glycine propionyl-L-carnitine on aerobic and anaerobic performance. Int J Sport Nutr Exerc Metab 2008, 18:19–36.PubMed Competing interests The authors declare that they have no competing interests. Authors’ contributions PJ was responsible Celecoxib for study design, data collection, statistical analysis, and manuscript preparation. EG was responsible for

data input and analysis as well as manuscript preparation. WB carried out data collection and input. IO carried out literature review, data collection and input. JH was responsible for data analysis and manuscript preparation.”
“Introduction Hepatocellular carcinoma is a sequel of chronic liver disease and shows high and increasing prevalence worldwide. In most cases it is associated with the presence of liver cirrhosis and has a poor prognosis with an overall median survival of 8 months in Austria [1]. To assess the survival of patients with hepatocellular carcinoma different prognostic models have been developed [2–5]. Although no staging system has emerged as standard, one of the most widely used survival model is the BCLC (Barcelona Clinic Liver Cancer) staging system [2] which appears to be the most comprehensive, as it links staging to treatment [5]. Treatment options which aim to obtain clinical cure include liver resection, liver transplantation and various forms of local ablation, such as percutaneous ethanol injection (PEI) or radiofrequency ablation.